Navigation Links
VTI Adds Patent For Its Modular Motion Preservation Spinal Implant

Minneapolis, MN – VTI, a MIS medical device company focused on lumber spine solutions, announced today that it has been granted a new patent from the U.S. Patent and Trademark Office. This patent relates to the company’s unique modular, in vivo assembly technology and its motion preservation, InterCushion® pipeline product. VTI now has over 25 patents and patent pending assets in its global intellectual property portfolio.

“The grant of this patent expands and lengthens VTI’s protection of our unique in vivo expansion technology for minimally invasive lumbar spine solutions. VTI is a world leader in lumbar spine focused motion preservation/disc nucleus replacement technology. This patent exemplifies our continued commitment to protect and broaden our intellectual property portfolio in this space. We are encouraged by the clinical results we are seeing from clinical trials using VTI’s modular technology in our InterCushion® product line,” commented Matthew R Kyle, President and CEO of VTI.

VTI’s InterCushion® lumbar spine motion preservation product has been successful in reducing pain, preserving disc, and halting modic changes in clinical trials in Canada. Currently, several patients are at or near 5 years’ post implantation with continued clinically successful outcomes.

Dr. Philip de Muelenaere stated “The potential value of an intervertebral nucleus replacement is linked to decreased future deterioration of the spinal motion segment. By maintaining disc height, the motion is maintained, stability is regained and long term collapse prevented. This protects the patency of the foramina, and decreases facet arthrosis which, apart from being a pain generator, will compromise the exiting nerve root.

The 5 year follow up MRI study proves that the prosthesis had maintained its position, maintained the disc height and kept the patients pain free."

VTI - Vertebral Technologies, Inc. is a privately held company based in Minneapolis, MN, USA. VTI is dedicated to the design, development, manufacturing and marketing of medical devices to address painful conditions of the spine through less-invasive surgical approaches. VTI’s products utilize its unique modular-assembly technology to deliver solutions optimized for both surgeons and their patients.

For more information visit, or contact Brian Thron at marketing(at)vti-spine(dot)com or +1.952-979-1811

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Balance Board Re-Invented: Patented New “Pono Board” Uniquely Designed to Engage the Body & Free the Mind
2. RegeneRx Receives Notice of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4.
3. World Patent Ratings Forecasts Modest Food Industry Growth and Rising Intangible Asset Valuations in 2017
4. Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations
5. World Patent Ratings Expects US Energy Companies To Outperform In 2017
6. World Patent Ratings Issues Intangible Asset Valuations Grades On North American Communications Equipment Sector
7. World Patent Ratings Releases Details of Conference Call on Transparency and Intangible Asset Valuation in the Biotechnology Industry
8. AxioMed Announces 15-year Exclusive Worldwide License on Proprietary Viscoelastic Material with the patent holder DSM
9. Acumed Reaches Agreement Regarding Patent Infringement of Acutrak® Screw
10. Male Inventors are Three Times More Likely to Apply for Patents than Women
11. NanoBio Awarded U.S. Patent for RSV Vaccine
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... ... 10, 2017 , ... Dr. Bob Harman, founder and CEO of VetStem ... The event entitled “Stem Cells and Their Regenerative Powers,” was held ... Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
Breaking Biology News(10 mins):